Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Other financing activities (2020 - 2025)

Historic Other financing activities for Ligand Pharmaceuticals (LGNYZ) over the last 5 years, with Q3 2025 value amounting to $14.8 million.

  • Ligand Pharmaceuticals' Other financing activities rose 696571.43% to $14.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 109562.45%. This contributed to the annual value of $426000.0 for FY2024, which is 5511.06% down from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Other financing activities is $14.8 million, which was up 696571.43% from $2000.0 recorded in Q2 2025.
  • Ligand Pharmaceuticals' Other financing activities' 5-year high stood at $14.8 million during Q3 2025, with a 5-year trough of -$121000.0 in Q1 2022.
  • In the last 4 years, Ligand Pharmaceuticals' Other financing activities had a median value of $64000.0 in 2024 and averaged $1.4 million.
  • Within the past 5 years, the most significant YoY rise in Ligand Pharmaceuticals' Other financing activities was 696571.43% (2025), while the steepest drop was 9649.12% (2025).
  • Over the past 4 years, Ligand Pharmaceuticals' Other financing activities (Quarter) stood at $42000.0 in 2022, then surged by 2159.52% to $949000.0 in 2023, then tumbled by 87.57% to $118000.0 in 2024, then skyrocketed by 12474.58% to $14.8 million in 2025.
  • Its Other financing activities was $14.8 million in Q3 2025, compared to $2000.0 in Q2 2025 and $71000.0 in Q1 2025.